Loading patent…
AssigneeAcorda Therapeutics, Inc.
InventorsElliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
Estimating the term…
A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
A composition comprising a plurality of modified cells prepared by extracting cells from a patient's blood and treating the cells with an enzyme that cleaves chondroitin sulfate proteoglycan, wherein the cells are selected from the group consisting of eosinophils, basophils, macrophages, and combinations thereof, and wherein the modified cells comprise at least one cell surface molecule that lacks chondroitin sulfate proteoglycan.
Dependencies are inferred from the claim text.